Core Insights - Nordson reported revenue of $669.46 million for the quarter ended January 2026, reflecting an 8.8% increase year-over-year and a surprise of +2.86% over the Zacks Consensus Estimate of $650.83 million [1] - The company's EPS for the quarter was $2.37, up from $2.06 in the same quarter last year, with an EPS surprise of +0.53% compared to the consensus estimate of $2.36 [1] Financial Performance Metrics - Net Sales for Industrial Precision Solutions reached $326.86 million, exceeding the average estimate of $308.5 million by two analysts, representing an 8.8% year-over-year increase [4] - Net Sales for Advanced Technology Solutions were reported at $149.42 million, surpassing the estimated $138 million by two analysts, showing a significant year-over-year increase of 23.1% [4] - Net Sales for Medical and Fluid Solutions amounted to $193.18 million, slightly below the average estimate of $204 million, indicating a minor year-over-year decline of 0.2% [4] Stock Performance - Over the past month, Nordson's shares have returned +11.6%, contrasting with a -1.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Nordson Corporation (NDSN) is experiencing strong growth in its Medical and Fluid Solutions segment, with organic sales increasing by 7.4% year over year in Q4 of fiscal 2025 [1][7] - The company has a positive outlook for fiscal 2026, projecting overall sales between $2.83 billion and $2.95 billion, indicating a year-over-year increase of 3.6% at the midpoint [3] Segment Performance - The Medical and Fluid Solutions segment's EBITDA margin improved by 40 basis points year over year in fiscal 2025, driven by organic sales growth, optimization of the manufacturing footprint, and strategic cost reduction initiatives [2][7] - The acquisition of Atrion Corp. in August 2024 has expanded Nordson's medical offerings in infusion and cardiovascular therapies, contributing to the segment's performance [2][7] Market Position and Valuation - Nordson's shares have increased by 6.8% over the past three months, outperforming the industry growth of 4.3% [6] - The company is currently trading at a forward price-to-earnings ratio of 21.51X, which is below the industry average of 21.84X [8] - The Zacks Consensus Estimate for NDSN's fiscal 2026 earnings has risen by 2.3% over the past 60 days [9]

Core Insights - Nordson reported revenue of $751.82 million for the quarter ended October 2025, reflecting a year-over-year increase of 1% and an EPS of $3.03 compared to $2.78 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $769 million, resulting in a surprise of -2.23%, while the EPS exceeded the consensus estimate of $2.93 by 3.41% [1] Financial Performance - Net Sales for Industrial Precision Solutions were $361.71 million, slightly above the average estimate of $360.05 million, but represented a year-over-year decline of 7.8% [4] - Net Sales for Advanced Technology Solutions reached $170.61 million, below the average estimate of $180.73 million, showing a year-over-year increase of 12.2% [4] - Net Sales for Medical and Fluid Solutions amounted to $219.5 million, also below the average estimate of $228.03 million, with a year-over-year increase of 9.6% [4] Stock Performance - Over the past month, Nordson's shares have returned -1.3%, contrasting with the Zacks S&P 500 composite's increase of 1.8% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Nordson Corporation's adjusted earnings for Q2 fiscal 2025 were $2.42 per share, exceeding the Zacks Consensus Estimate of $2.36, marking a 3% year-over-year increase [1] - Revenues reached $682.9 million, a 5% increase from the previous year, driven by the Advanced Technology Solutions segment and contributions from acquisitions, surpassing the consensus estimate of $674 million [1] Revenue Performance - Organic sales declined by 2.4% year over year, primarily due to weakness in polymer processing and industrial coatings [2] - Acquisitions positively impacted sales by 7.8%, while foreign currency translation had a negative effect of 0.4% [2] - The backlog increased approximately 5% sequentially [2] Regional Revenue Breakdown - Asia Pacific revenues were $218 million, up 25.2% year over year [3] - European revenues decreased by 5.3% to $172.5 million [3] - Revenues in the Americas decreased by 0.7% to $292.5 million [3] Segment Performance - Industrial Precision Solutions revenues were $318.8 million, down 7.6% year over year, contributing 46.7% to total revenues [3] - Medical and Fluid Solutions revenues were $202.8 million, up 20% year over year, contributing 29.7% to total revenues [4] - Advanced Technology Solutions revenues were $161.3 million, up 18% year over year, representing 23.6% of total revenues [5] Margin and Expense Analysis - Cost of sales increased by 8.5% year over year to $309 million, with gross profit at $373.9 million, a 2.2% increase [6] - Gross margin decreased by 150 basis points to 54.7% [6] - Selling and administrative expenses rose by 4% year over year to $205.2 million [7] - Adjusted EBITDA was $217.2 million, up 6.8% year over year, with an operating margin of 24.7%, down 120 basis points [7] Balance Sheet and Cash Flow - Cash and cash equivalents at the end of Q2 fiscal 2025 were $130.2 million, up from $116 million at the end of fiscal 2024 [8] - Long-term debt increased to $2.12 billion from $2.10 billion at the end of fiscal 2024 [8] - Net cash generated from operating activities in the first six months of fiscal 2025 was $278.3 million, down 5.7% year over year [9] Dividend and Share Buyback - Dividends paid in the first six months of fiscal 2025 totaled $88.9 million, a 14.3% increase from $77.8 million in the previous year [10] - Treasury share purchases amounted to $146.3 million, significantly up from $7.9 million in the year-ago period [10] Future Outlook - For Q3 fiscal 2025, Nordson projects sales between $710 million and $750 million, with adjusted earnings expected to be between $2.55 and $2.75 per share [11]